Literature DB >> 17912464

Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus.

Yoshiji Yamada1, Hitoshi Matsuo, Sachiro Watanabe, Kimihiko Kato, Kazuhiro Yajima, Takeshi Hibino, Kiyoshi Yokoi, Sahoko Ichihara, Norifumi Metoki, Hidemi Yoshida, Kei Satoh, Yoshinori Nozawa.   

Abstract

Although several environmental factors, including a high-calorie diet and physical inactivity, influence the development of type 2 diabetes mellitus, genetic factors have been shown to contribute to individual susceptibility to this condition. The purpose of the present study was to identify gene polymorphisms that confer susceptibility or resistance to type 2 diabetes mellitus, and thereby to contribute to assessment of the genetic risk for this condition. The study population comprised 5259 unrelated Japanese individuals (2980 men, 2279 women), including 1640 subjects with type 2 diabetes mellitus (1071 men, 569 women) and 3619 controls (1909 men, 1710 women). The genotypes for 94 polymorphisms of 67 genes were determined with a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. Evaluation of genotype distributions by the chi-square test revealed that the 13989-->G (Ile118Val) polymorphism of the cytochrome P450, subfamily IIIA, polypeptide 4 gene (CYP3A4) was significantly (false discovery rate, 0.000009) associated with the prevalence of type 2 diabetes mellitus. Multivariable logistic regression analysis with adjustment for age and sex also revealed that the 13989-->G (Ile118Val) polymorphism of CYP3A4 was significantly (P=0.00002) associated with the prevalence of type 2 diabetes mellitus, with the AG genotype being protective against this condition. Genotyping for CYP3A4 may thus prove informative for assessment of the genetic risk for type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912464

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  10 in total

1.  Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.

Authors:  Sabina Semiz; Tanja Dujic; Barbara Ostanek; Besim Prnjavorac; Tamer Bego; Maja Malenica; Janja Marc; Adlija Causevic
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

2.  Polymorphism of CYP3A4 2 and eNOS genes in the diabetic patients with hyperlipidemia undergoing statin treatment.

Authors:  Kaiser Jamil; Vidya Kandula; Ramoji Kandula; M Asimuddin; Sindu Joshi; Shiva Kumar Yerra
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

3.  Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model.

Authors:  Camille Marciniak; Oscar Chávez-Talavera; Robert Caiazzo; Thomas Hubert; Lorea Zubiaga; Gregory Baud; Audrey Quenon; Amandine Descat; Emmanuelle Vallez; Jean François Goossens; Mostafa Kouach; Vincent Vangelder; Mathilde Gobert; Mehdi Daoudi; Bruno Derudas; Pascal Pigny; André Klein; Valéry Gmyr; Violeta Raverdy; Sophie Lestavel; Blandine Laferrère; Bart Staels; Anne Tailleux; François Pattou
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-01-25       Impact factor: 4.310

4.  Gene-environment interactions in the development of complex disease phenotypes.

Authors:  Rosemarie G Ramos; Kenneth Olden
Journal:  Int J Environ Res Public Health       Date:  2008-03       Impact factor: 3.390

Review 5.  Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis

Authors:  Imadeldin Elfaki; Rashid Mir; Fahad M Almutairi; Faisel M Abu Duhier
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24

6.  A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus.

Authors:  Shui-Han Zhang; Yu-Hui Qin; Dan He; Jian-Hua Huang; Zhe-Yu Zhang; Qing Du; Wei-Jun Peng; Rong Yu; Si-Fang Zhang
Journal:  Drug Des Devel Ther       Date:  2019-11-28       Impact factor: 4.162

7.  Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner.

Authors:  Anandita Pal; Abrar E Al-Shaer; William Guesdon; Maria J Torres; Michael Armstrong; Kevin Quinn; Traci Davis; Nichole Reisdorph; P Darrell Neufer; Espen E Spangenburg; Ian Carroll; Richard P Bazinet; Ganesh V Halade; Joan Clària; Saame Raza Shaikh
Journal:  FASEB J       Date:  2020-06-24       Impact factor: 5.191

8.  CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study.

Authors:  Wondmagegn Tamiru Tadesse; Eulambius Mathias Mlugu; Workineh Shibeshi; Wondwossen Amogne Degu; Ephrem Engidawork; Eleni Aklillu
Journal:  J Pers Med       Date:  2022-06-30

9.  Association of CYP7A1 and CYP2E1 Polymorphisms with Type 2 Diabetes in the Chinese Han Populations.

Authors:  Lihong Zhang; Jingjing Tang; Yindi Wang; Xiang Wang; Fang Wang
Journal:  Pharmgenomics Pers Med       Date:  2022-09-21

10.  Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition.

Authors:  Abrar E Al-Shaer; Nicole Buddenbaum; Saame Raza Shaikh
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-03-29       Impact factor: 5.228

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.